CD8A and neoplasm: We have previously demonstrated that RHDV-VLP are phagocytosed by both murine and human antigen presenting cells (APC) and that the heterologous VLP-associated antigens can be presented to and recognized by CD8+ T cells to generate anti-tumour activity [17]–[19].